SEC Filing Summary: Cyclacel Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. on January 27, 2010. The report addresses a regulatory status update regarding the company's listing on The NASDAQ Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes
- Regulatory Compliance: The Company received notification from NASDAQ that it has regained compliance with the minimum $50 million market value of listed securities requirement.
- Listing Status: The Company currently complies with all other applicable standards for continued listing on The NASDAQ Global Market.
- Delisting Proceeding: The previously disclosed delisting proceeding has been officially closed.
Outlook and Management Commentary
Management confirmed that shares of common and preferred stock will continue to trade on The NASDAQ Global Market. No forward-looking guidance, risk factors, or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the current market capitalization to ensure continued compliance with the $50 million threshold.
- Confirm the trading status of common and preferred stock on The NASDAQ Global Market.
- Review the attached press release (Exhibit 99.1) for additional details on the compliance determination.